Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification
Novartis India Ltd · Financial Result · 04 Nov 2026, 5:38 am
Evonile Pharma Reports Q2 FY27 Results and ₹800 Crore Debt Clarification Evonile Pharma Limited (formerly Novartis India) clarified its total outstanding bank debt and financial indebtedness at ₹800 crore as of 30th Sep'26 with zero defaults. For Q2 ended 30th Sep'26, revenue from operations dropped 37.9% YoY to ₹560.5 million. The company posted a net loss of ₹775.4 million versus a profit of ₹242.2 million in Q2 FY26, impacted by an exceptional item of ₹682.6 million following the termination of distribution arrangements. It also capitalized ₹12,900.0 million in intangible assets for trademark acquisitions.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Press Release - Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026. · 04 Nov 2026
